In response, a number of Point-of-Care (POC) rapid and relatively affordable tests for SARS-CoV-2 have been recently developed. In addition, an indispensable goal for the control of the COVID-19 pandemic is the capacity for mass population screening, a condition that demands rapid and cost-efficient assay approaches. In consequence, there is an urgent need for diagnostic tools able not only to reliably identify infected individuals-i.e., the source of infection-but also to determine if the infection is in the acute phase. The current outbreak of the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) has presented epidemiologists around the globe with an unpreceded challenge: the ability to reliably predict the spread of this novel highly contagious coronavirus and, in consequence, apply appropriate quarantine measures to prevent the transmission of the infection. In this way, we demonstrate that the novel biosensor can be potentially applied for the mass screening of SARS-CoV-2 surface antigens without prior sample processing, therefore offering a possible solution for the timely monitoring and eventual control of the global coronavirus pandemic.
#123d design portable portable#
Furthermore, the biosensor was configured as a ready-to-use platform, including a portable read-out device operated via smartphone/tablet. In addition, no cross-reactivity was observed against the SARS-CoV-2 nucleocapsid protein. The novel biosensor provided results in an ultra-rapid manner (3 min), with a detection limit of 1 fg/mL and a semi-linear range of response between 10 fg and 1 μg/mL. We demonstrate that the attachment of the protein to the membrane-bound antibodies resulted in a selective and considerable change in the cellular bioelectric properties measured by means of a Bioelectric Recognition Assay.
The biosensor is based on membrane-engineered mammalian cells bearing the human chimeric spike S1 antibody. We herewith report the proof-of-concept development of a biosensor able to detect the SARS-CoV-2 S1 spike protein expressed on the surface of the virus. However, please note that you can enable or disable cookies by following the instructions of your browser.One of the key challenges of the recent COVID-19 pandemic is the ability to accurately estimate the number of infected individuals, particularly asymptomatic and/or early-stage patients. If you want you can disable cookies from Google Analytics. Cookies added by Google Analytics are governed by the privacy policies of Google Analytics. We use Google Analytics to collect anonymous statistical information such as the number of visitors to our site. So when you access our website, in compliance with Article 22 of Law 34/2002 of the Information Society Services, in the analytical cookies treatment, we have requested your consent to their use.
0 kommentar(er)
